High Throughput Screen for Myotonic Dystrophy Type 1
High Throughput Screen for Myotonic Dystrophy Type 1
批准号:
8209483
负责人:
NOURI NEAMATI
金额:
$4.08万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-22 至 2012-06-30
关键词:
3&apos Untranslated RegionsAdultAffectAntisense OligonucleotidesBindingBiological AssayBiologyCellsChemical StructureConsultDataDefectDevelopmentDiseaseEctopic ExpressionFDA approvedGenesHousingHumanIn VitroLeadLibrariesLinkMachine LearningMediatingMolecularMuscular DystrophiesMyoblastsMyotonic DystrophyNeuromuscular DiseasesNuclear RNAPathologyPatientsPatternPharmaceutical PreparationsPhenotypeProbabilityPropertyProtein FamilyProtein KinaseProtein Kinase C AlphaRNARNA SplicingScreening procedureSeriesStructure-Activity RelationshipSystemTestingTherapeuticToxic effectTranscriptValidationbasehigh throughput screeningimprovedin vivomouse modelmutantprotein complexsmall moleculesmall molecule librariestherapeutic targettranscription factor
中文摘要
描述(由申请人提供):肌强直性营养不良症(DM1)是人类最常见的成人发病肌肉营养不良症。目前,没有治愈DM1和相关疾病的药物或FDA批准的药物。DM1的分子基础是蛋白激酶基因DMPK 3'非翻译区ctg重复序列的扩增。这种缺陷导致编码扩展CUG重复序列(CUGexp)的突变DMPK rna的表达,形成大的核内rna -蛋白复合物或灶。CUGexp RNA的表达导致异常的RNA剪接,这反过来又与DM1病理的关键特征的发展有关。我们假设降解或分散DM1细胞中CUGexp rna的小分子可以重建正常的剪接模式并逆转DM1病理。为了验证这一假设,我们开发了初级HTS和二级命中验证试验,以确定在不影响正常转录的情况下改变CUGexp rna生物学的小分子。我们的内部文库是使用强大的机器学习化学信息学平台开发的,由40,000个高度多样化的小分子组成,代表了超过100万种化合物的文库。对该文库中的2500个小分子进行初步筛选,最终鉴定出一种有效的先导化合物MDI16,它可以逆转DM1患者成肌细胞和DM1 HSALR小鼠模型中的异常RNA剪接模式。为了确定其他有效的先导化合物,我们提出以下建议:目的1。在MLPCN中心实施初级HTS和二级命中验证试验。目标2。测试命中在三级细胞为基础的分析,以确定高度有效的分子,逆转四种关键细胞DM1表型。目标3。表征先导化合物的选择性和毒性,并使用实验室开发的一套基于细胞的测定方法确定其在细胞水平上的作用机制。目标4。我们将与MLPCN中心合作,反复细化先导化合物的化学结构,以优化药理学性质并建立构效关系。
英文摘要
DESCRIPTION (provided by applicant): Myotonic dystrophy (DM1) is the most common adult onset muscular dystrophy in humans. Currently, there is no cure or an FDA approved drug for DM1 and related diseases. The molecular basis of DM1 is the expansion of a CTG-repeat sequence in the 3' untranslated region of the protein kinase gene, DMPK. This defect results in the expression of mutant DMPK RNAs encoding expanded CUG repeats (CUGexp) that form large intra nuclear RNA-protein complexes or foci. Expression of CUGexp RNAs leads to abnormal RNA splicing, which in turn has been linked to the development of key features of DM1 pathology. We hypothesize that small molecules that degrade or disperse CUGexp RNAs in DM1 cells can re-establish normal splice patterns and reverse DM1 pathology. To test this hypothesis, we developed a primary HTS and a secondary hit validation assay to identify small-molecules that alter the biology of CUGexp RNAs without affecting the normal transcript. Our in house library was developed using a robust machine learning chemoinformatics platform and consists of 40,000 highly diverse small-molecules representing a library of over a million compounds. An initial screen of 2,500 small molecules from this library resulted in the identification of a potent lead compound, MDI16, which reverses aberrant RNA splice patterns in both DM1 patient myoblasts and in the HSALR mouse model for DM1. In a concerted effort to identify other potent lead compounds we propose the following: Aim 1. Implement primary HTS and the secondary hit validation assay in the MLPCN center. Aim 2. Test hits in tertiary cell-based assays to identify highly potent molecules that reverse four key cellular DM1 phenotypes. Aim 3. Characterize the selectivity and toxicity of lead compounds and identify their mechanism of action at the cellular level using a set of cell-based assays developed in the lab. Aim 4. In conjunction with the MLPCN center, we will refine the chemical structure of lead compounds reiteratively to optimize pharmacological properties and establish structure-activity relationships.
PUBLIC HEALTH RELEVANCE: Lay Summary Myotonic dystrophy type 1 is a neuromuscular disorder for which there is no treatment or cure. Over the past few years exciting strides in our understanding of the mechanistic basis of this disorder have been made. Thus the field is poised to make a major breakthrough and develop a drug for this disorder. We have developed a sensitive high throughput screen (HTS) to identify compounds that cure or ameliorate pathologies associated with myotonic dystrophy. Currently we have discovered potent molecules, which rescue DM1 pathology in both DM1 patient myoblasts and in DM1 mouse models. As our screens have been proven to identify potent molecules that rescue DM1 pathology, in this application we propose to identify other lead compounds by screening the MLPCN chemical library with our HTS. Identification of multiple leads will greatly improve the probability of a small molecule therapy for DM1.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer
-
批准号:10684845
-
项目类别:
-
资助金额:$46.36万
-
财政年份:2022
-
负责人:NOURI NEAMATI
-
依托单位:
Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer
-
批准号:10675586
-
项目类别:
-
资助金额:$53.14万
-
财政年份:2022
-
负责人:NOURI NEAMATI
-
依托单位:
gp130 as a novel therapeutic target in ovarian cancer
-
批准号:8797755
-
项目类别:
-
资助金额:$37.69万
-
财政年份:2015
-
负责人:NOURI NEAMATI
-
依托单位:
Efficacy of PDI inhibitors in glioblastoma
-
批准号:8858876
-
项目类别:
-
资助金额:$48.63万
-
财政年份:2015
-
负责人:NOURI NEAMATI
-
依托单位:
gp130 as a novel therapeutic target in ovarian cancer
-
批准号:8994723
-
项目类别:
-
资助金额:$37.63万
-
财政年份:2015
-
负责人:NOURI NEAMATI
-
依托单位:
ROS-targeted therapy for pancreatic cancer
-
批准号:9102041
-
项目类别:
-
资助金额:$46.1万
-
财政年份:2015
-
负责人:NOURI NEAMATI
-
依托单位:
gp130 as a novel therapeutic target in ovarian cancer
-
批准号:9903250
-
项目类别:
-
资助金额:$36.5万
-
财政年份:2015
-
负责人:NOURI NEAMATI
-
依托单位:
Efficacy of PDI inhibitors in glioblastoma
-
批准号:9086289
-
项目类别:
-
资助金额:$48.61万
-
财政年份:2015
-
负责人:NOURI NEAMATI
-
依托单位:
ROS-targeted therapy for pancreatic cancer
-
批准号:8963517
-
项目类别:
-
资助金额:$46.1万
-
财政年份:2015
-
负责人:NOURI NEAMATI
-
依托单位:
Inhibition of HIV-1 Integrase-LEDGF/P75 Interactions
-
批准号:7897668
-
项目类别:
-
资助金额:$20.4万
-
财政年份:2009
-
负责人:NOURI NEAMATI
-
依托单位:
Inhibition of HIV-1 Integrase-LEDGF/P75 Interactions
-
批准号:7756315
-
项目类别:
-
资助金额:$24.6万
-
财政年份:2009
-
负责人:NOURI NEAMATI
-
依托单位:
Integrin avb3 targeted drug design, delivery, and imaging
-
批准号:7384532
-
项目类别:
-
资助金额:$22.98万
-
财政年份:2007
-
负责人:NOURI NEAMATI
-
依托单位:
Integrin avb3 targeted drug design, delivery, and imaging
-
批准号:8136333
-
项目类别:
-
资助金额:$20.69万
-
财政年份:2007
-
负责人:NOURI NEAMATI
-
依托单位:
Integrin avb3 targeted drug design, delivery, and imaging
-
批准号:7663242
-
项目类别:
-
资助金额:$21.4万
-
财政年份:2007
-
负责人:NOURI NEAMATI
-
依托单位:
Integrin avb3 targeted drug design, delivery, and imaging
-
批准号:7502581
-
项目类别:
-
资助金额:$21.4万
-
财政年份:2007
-
负责人:NOURI NEAMATI
-
依托单位:
Integrin avb3 targeted drug design, delivery, and imaging
-
批准号:7901354
-
项目类别:
-
资助金额:$21.33万
-
财政年份:2007
-
负责人:NOURI NEAMATI
-
依托单位:
CORE--ANALYTIC
-
批准号:7082602
-
项目类别:
-
资助金额:$13.04万
-
财政年份:2006
-
负责人:NOURI NEAMATI
-
依托单位:
CORE--ANALYTIC
-
批准号:7626295
-
项目类别:
-
资助金额:$20.37万
-
财政年份:--
-
负责人:NOURI NEAMATI
-
依托单位:
CORE--ANALYTIC
-
批准号:7864197
-
项目类别:
-
资助金额:$20.93万
-
财政年份:--
-
负责人:NOURI NEAMATI
-
依托单位:
CORE--ANALYTIC
-
批准号:7447872
-
项目类别:
-
资助金额:$20.18万
-
财政年份:--
-
负责人:NOURI NEAMATI
-
依托单位:
海外基金